Akebia Therapeutics (AKBA) Stock Price
$1.8 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
3 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Akebia Therapeutics, AI stock picks, stock alerts and much more.
AKBA AI Stock Analysis
AI stock analysis for AKBA is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Akebia Therapeutics (AKBA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Akebia Therapeutics (AKBA) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Akebia Therapeutics (AKBA), currently trading at $1.8, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About AKBA
-
Akebia Therapeutics, Inc.
-
Symbol
AKBA
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
392.7M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.62 2% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.24 0.9% |
2 |
 |
Moderna MRNA |
$35.53 5.3% |
4 |
 |
Anavex Life Sciences AVXL |
$8.35 3.8% |
6 |
 |
BridgeBio Pharma BBIO |
$36.85 0.1% |
6 |
News
AKBA Alternative Data
Web Traffic
Akebia Therapeutics receives an estimated 17165 monthly visitors to akebia.com.
-
Web Traffic
17165
-
Change from Previous Month
23%
-
3 Month Change
134.2%
-
YoY Change
134.2%
News Mentions
Akebia Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Reddit Mentions
Akebia Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
Twitter Followers
Akebia Therapeutics has 2,041 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.2% over the last month.
-
Twitter Followers
2041
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
3.1%
Facebook Engagement
Akebia Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Instagram Followers
Akebia Therapeutics has 417 Instagram Followers on its main Instagram account, up by 0.7% over the last month.
-
Instagram Followers
417
-
Daily Change
0.2%
-
1 Month Change
0.7%
-
3 Month Change
1.5%
LinkedIn Followers
38,370 are following Akebia Therapeutics on LinkedIn, up by 1% over the last month.
-
LinkedIn Followers
38370
-
Daily Change
0%
-
1 Month Change
1%
-
3 Month Change
1.9%
Job Postings
Akebia Therapeutics currenly has an estimated 15 open job postings, up by 15.4% over the last month.
-
Job Postings
15
-
Daily Change
6.3%
-
1 Month Change
15.4%
-
3 Month Change
50%
LinkedIn Employees
According to LinkedIn, Akebia Therapeutics has 261 employees, down by -0.8% over the last month.
-
LinkedIn Employees
261
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
4.8%
Business Outlook
-
Business Outlook
50
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
AKBA Financials
AKBA Key Metrics
-
Total Revenue
$37.4M
-
Net Income
-$20M
-
Earnings per Share
-$0.0953
-
Free cash flow
-$6.7M
-
EBITDA
-$4M
-
EBITDA Ratio
-0.106979
-
Total Assets
$207.1M
AKBA 2-year Revenue & Income
AKBA 2-year Free Cash Flow
AKBA Technicals
AKBA SMA
AKBA RSI
FAQ
What's the current price of Akebia Therapeutics (AKBA) Stock?
The price of an Akebia Therapeutics (AKBA) share is $1.8.
What's the market cap of Akebia Therapeutics?
The current market cap of Akebia Therapeutics is 392.7M.
Should I buy or sell AKBA?
Akebia Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Akebia Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Akebia Therapeutics a good investment?
The current analysis of Akebia Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Akebia Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Akebia Therapeutics (AKBA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Akebia Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Akebia Therapeutics (AKBA) that investors often compare it to?
Akebia Therapeutics (AKBA) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Akebia Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Akebia Therapeutics' stock price to be around $1.8 in 2026. Starting from the current price of $1.8, this represents a 0.1% change in price, indicating a neutral outlook for the stock.
How to buy Akebia Therapeutics (AKBA) Stock?
Akebia Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Akebia Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.